Finance

Beta
Lists
LRMR:NASDAQ
Larimar Therapeutics Inc
$3.16
+3.77%
(+0.12) 1D
Jul 1, 12:17:18 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LRMR...
Open
$3.04
High
$3.25
Low
$3.01
Mkt. cap
327.75M
Avg. vol.
2.55M
Volume
1.23M
52-wk high
$6.42
52-wk low
$2.72
EPS
-$2.08
Beta
0.83
Shares outstanding
103.88M
No. of employees
71
Open
$3.04
High
$3.25
Low
$3.01
Mkt. cap
327.75M
Avg. vol.
2.55M
Volume
1.23M
52-wk high
$6.42
52-wk low
$2.72
EPS
-$2.08
Beta
0.83
Shares outstanding
103.88M
No. of employees
71
News stories
From sources across the web
About Larimar Therapeutics Inc
CEO-
Employees71
Founded2005
HeadquartersBala Cynwyd, Pennsylvania, United States
SectorBiotechnology
Websitelarimartx.com
Analyst ratings
Based on 6 analysts giving stock ratings to LRMR in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for LRMR in the last 3 months.
Highest
Current $3.16
$25.00 (+689.89%)
Average
$13.00 (+310.74%)
Lowest
$5.00 (+57.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Laura Chico
Wedbush
Buy
Maintained
$12.00
+279.1%
06/30/2026
Christopher Chen
Robert W. Baird
Buy
Maintained
$5.00
+58%
06/30/2026
Tessa Romero
J.P. Morgan
Buy
Reiterated
$9.00
+184.4%
06/29/2026
Samantha Semenkow
Citi
Buy
Maintained
$14.00
+342.3%
06/30/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
06/29/2026
Francois Brisebois
LifeSci Capital
Buy
Maintained
$25.00
+689.9%
06/29/2026
Catherine Novack
JonesTrading
Buy
Maintained
$13.00
+310.7%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
23.27M
44.83M
59.17M
24.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.52M
4.67M
4.84M
6.19M
Operating expense
27.79M
49.50M
64.02M
31.12M
Total operating expenses
27.79M
49.50M
64.02M
31.12M
Operating income
-27.79M
-49.50M
-64.02M
-31.12M
Other non operating income
1.61M
1.79M
1.52M
1.50M
EBT including unusual items
-26.18M
-47.71M
-62.50M
-29.61M
EBT excluding unusual items
-26.18M
-47.71M
-62.50M
-29.61M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.18M
-47.71M
-62.50M
-29.61M
Net profit margin
-
-
-
-
Earnings per share
-0.41
-0.61
-0.73
-0.31
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.70M
-49.41M
-63.93M
-31.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer